Biotech is in a period of uncertain times. Following record growth and profits, the sector is now in “Biotech Winter,” with share values down and venture capital funds scarce, even for formerly white-hot categories like Oncology drugs. As a result, biotech companies are retrenching, prioritizing their portfolios, rethinking clinical development programs, and conserving funds.
This new reality may not necessarily require a rewrite of a company’s overall strategy, but it does require a good hard look in the mirror to answer important questions:
What is the Pharma buyer or investor looking for?
Is my program sufficiently differentiated?
How do I create a compelling story, especially for early-stage and developing assets?
How do I balance value creation with risk reduction?
“Biotech Decision-Making During Uncertain Times” brings together a cast of experienced biotech, pharma, and investment pros for a spirited dialogue around these and other issues, including life after the Biotech Winter. For those currently immersed in a pharma development program, initiating a novel Immuno-Oncology program, or conjuring a new twist on a known precision Oncology treatment, this webinar offers insights, direction, and inspiration. Watch now.